Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Northwest Biotherapeutics, Inc. (NWBO) had Return on Equity of 99.80% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$1.38M |
|
$-61.48M |
|
-- |
|
$1.38M |
|
$61.29M |
|
$-59.91M |
|
$-0.79M |
|
$-60.70M |
|
$-60.70M |
|
$-60.16M |
|
$-60.16M |
|
$-60.16M |
|
$-60.16M |
|
$-59.91M |
|
$-55.96M |
|
1.46B |
|
1.46B |
|
$-0.04 |
|
$-0.04 |
|
| Balance Sheet Financials | |
$5.52M |
|
$17.41M |
|
$75.77M |
|
$81.29M |
|
$91.70M |
|
$0.33M |
|
$37.16M |
|
$128.86M |
|
$-60.28M |
|
$-101.38M |
|
$-47.57M |
|
1.56B |
|
| Cash Flow Statement Financials | |
$-44.76M |
|
$-1.81M |
|
$49.33M |
|
$2.17M |
|
$3.04M |
|
$0.86M |
|
$1.21M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.06 |
|
-- |
|
-- |
|
-0.01 |
|
-1.09 |
|
100.00% |
|
-4347.90% |
|
-4347.90% |
|
-4061.18% |
|
-4404.86% |
|
-4461.32% |
|
$-46.27M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
99.80% |
59.34% |
|
-74.01% |
|
127.34% |
|
$-0.03 |
|
$-0.03 |
|
$-0.03 |
|